Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ETCompany ParticipantsJames E.

Amgen Inc. closed 15.40% below its 52-week high of $346.85, which the company reached on July 25th.

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Amgen Manufacturing Limited LLC has received the U.S. Environmental Protection Agency’s Energy Star certification for its facility in Juncos, Puerto Rico, placing it among the most energy-efficient ...

Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

With markets bracing for key developments—including updates from U.S.–China trade talks and the release of CPI and PPI inflation data on Wednesday and Thursday—investors may look to the relative ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 10, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Patients with AAV who received avacopan vs standard glucocorticoid-based regimens had lower exposure-adjusted rates of AEs, infections, and neutropenia/lymphopenia.